

1 Supplementary table 1. Number of samples with discrepant Onclarity and Cobas hrHPV
2 results.

| | Aptima positive | Total |
|------------------------------------|-----------------|-------|
| Onclarity positive, Cobas negative | 7 | 14 |
| Onclarity negative, Cobas positive | 5 | 26 |
| Total | 12 | 40 |

3

4 Supplementary table 2. Several genotype combination of interest

| HPV genotype | Number of CIN2/3+ | Number of sample with the genotype | Relative risk to CIN2/3+ (95% CI)* |
|---|-------------------|------------------------------------|------------------------------------|
| hrHPV +ve, 16 +ve or -ve, 33/58 -ve, 56/59/66 +ve | 8 | 59 | 4.32 (1.55-12.01) |
| hrHPV +ve, 16 +ve, 33/58 -ve, 56/59/66 - ve, 52 +ve | 4 | 9 | 11.13 (3.58-34.61) |
| hrHPV +ve, 16 -ve, 33/58 +ve, 52 +ve | 8 | 15 | 12.58 (4.78-33.10) |

5 *: Risk relative to hrHPV negative as presented in Table 5.